ERBB2 and laryngotracheoesophageal cleft: In addition to FGFR4, other kinases such as IRAK4, CKMT1B, PKN1, MAPKAPK3, Pim1, and STK4 in CRC, ALK in LC, CSNK1A1L and Her2/Neu in BC, and ECPKA in Non-Hodgkin’s lymphoma, breast, colon, and most highly incident cancers have been observed both as target of autoantibodies with diagnostic ability and as potential targets for therapy (30, 128, 190, 196, 197).